Cocrystal Pharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cocrystal Pharma, Inc. on September 9, 2026. The report discloses a material clinical development milestone under Item 7.01 (Regulation FD Disclosure).
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a clinical trial update and does not contain financial statements.
Material Changes and Clinical Update
- Event: The Company announced that the last subject has been dosed in its Phase 1b norovirus challenge study (ClinicalTrials.gov Identifier: NCT07198139).
- Drug Candidate: CDI-988.
- Indication: Evaluation of CDI-988 as both a preventive and treatment for norovirus infections.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future financial performance, or specific risk factors beyond the standard disclaimer that the press release information is not deemed "filed" under Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for details on the study design and expected timeline for data readout.
- Confirm the status of the Phase 1b study on ClinicalTrials.gov using identifier NCT07198139.
- Review subsequent filings for any safety data or preliminary efficacy results following the completion of dosing.